Denmark's Ascendis Pharma Q1 revenue more than doubles on YORVIPATH sales

Ascendis Pharma A/S

07/05/2026 12:41

Overview

Denmark biopharma's Q1 revenue more than doubled yr/yr, driven by YORVIPATH sales

Company swung to net profit, aided by one-time deferred tax asset recognition

Ascendis agreed to sell Rare Pediatric Disease Priority Review Voucher for $187.5 mln

Outlook

Company expects EMA decision on YUVIWEL in Q4 2026

Interim Week 78 data from COACH trial expected in Q2 2026

Enrollment completion for reACHin trial in infants anticipated in Q3 2026

Result Drivers

YORVIPATH SALES GROWTH - Revenue surge was mainly due to increased YORVIPATH sales, including more than 1,000 new U.S. patient enrollments and expanded market access in Europe

COMMERCIAL EXPANSION COSTS - Higher selling, general, and administrative expenses were driven by commercial expansion, including global launch activities

SKYTROFA SALES DECLINE - SKYTROFA revenue fell to €44 mln from €51 mln a year earlier

Company press release: ID:nGNXc5rGvq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
EUR 9.75


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)